KINKI CRITERIA FOR THE SUBCLASSIFICATION OF INTERMEDIATE-STAGE HEPATOCELLULAR CARCINOMA: CLINICAL IMPLICATION
Main Article Content
Abstract
Purpose: to subclassify the intermediate stage hepatocellular carcinoma (HCC) by using Kinki criteria.
Materials and methods: A cross-sectional study was conducted on 109 patients with intermediate stage HCC from 01/2022 to 08/2023 at Hue University of Medicine and Pharmacy Hospital and Hue Center Hospital. HCC was diagnosed using the practice guideline of the Ministry of Health 2020, classified into the intermediate stage according to BCLC 2012. Intermediate stage HCC was then subclassified by using Kinki criteria. Treatment indications were documented. Clinical implication of Kinki criteria was reviewed and discussed.
Results: Mean age: 64.2 ± 13 years, male: female ratio 7:1. Average tumor size: 8.9 ± 3.6 cm. Subclassification of 109 intermediate stage HCC (BCLC-B) included 21 (19.3%) B1, 76 (69.7%) B2, and 12 (11%) B3. The subgroup B3 was further classified as B3a (n=2, 1.8%) and B3b (n=10, 9.2%). Treatment indications followed BCLC-B 2012 recommendation in 47.7% of cases (TACE: transarterial chemoembolization) whereas 52.3% were outside, including resection (22%), systemic chemotherapy (18.3%), conservative (9.2%) and radiofrequency ablation (2.8%). Comparing clinical treatment indications and recommendations of Kinki criteria we found: 100% of patients were in group B1; 76.4% of patients in group B2 and 66.7% of patients in group B3 received treatment corresponding to the recommendation of Kinki criteria.
Conclusion: Intermediate-stage HCC encompasses a wide and heterogeneous population in terms of performance status, tumor burden and underlying liver function. Subclassification of patients in this stage using Kinki criteria helps optimize treatment strategies and improve patient prognosis.
Keywords
Hepatocellular carcinoma, computed tomography, Child-Pugh, Kinki criteria
Article Details
References
2. Bolondi, Luigi, et al. (2012), Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions, Seminars in liver disease, Thieme Medical Publishers, pp. 348-359.
3. European Association For The Study Of The Liver (2018), “EASL clinical practice guidelines: management of hepatocellular carcinoma”, Journal of hepatology. 69(1), pp. 182-236.
4. Yi, Peng-Sheng, Hong Wang, and Jian-Shui Li (2020), “Evolution and current status of the subclassification of intermediate hepatocellular carcinoma”, World journal of gastrointestinal surgery. 12(3), pp. 85-92.
5. Kudo, Masatoshi, et al. (2015), “Subclassification of BCLC B stage hepatocellular carcinoma and treatment strategies: proposal of modified Bolondi’s subclassification (Kinki criteria)”, Digestive diseases. 33(6), pp. 751-758.
6. Bộ Y tế (2020), “Hướng dẫn chẩn đoán và điều trị ung thư biểu mô tế bào gan”, 3129_QD-BYT, pp. tr.8-11.
7. Arizumi, Tadaaki, et al. (2016), “Validation of Kinki criteria, a modified substaging system, in patients with intermediate stage hepatocellular carcinoma”, Digestive Diseases. 34(6), pp. 671-678.
8. Yamamoto, Masateru, et al. (2021), “Significance of liver resection for intermediate stage hepatocellular carcinoma according to subclassification”, BMC Cancer. 21(1), p. 668.
9. Geschwind, Jean-Francois H, et al. (2016), “Use of transarterial chemoembolization (TACE) and sorafenib in patients with unresectable hepatocellular carcinoma: US regional analysis of the GIDEON registry”, Liver Cancer. 5(1), pp. 37-46.
10. Kudo, M (2015), “Immune checkpoint blockade in hepatocellular carcinoma”, Liver Cancer. 4(4), p. 201.
11. Kawaoka, Tomokazu, et al. (2018), “Comparison of hepatic arterial infusion chemotherapy between 5 fluorouracilbased continuous infusion chemotherapy and low-dose cisplatin monotherapy for advanced hepatocellular carcinoma”, Hepatology Research. 48(13), pp. 1118-1130.
12. Zhong, Jian-Hong, et al. (2013), “Comparison of long-term survival of patients with BCLC stage B hepatocellular carcinoma after liver resection or transarterial chemoembolization”, PloS one. 8(7), p. e68193.
13. Reig, Maria, et al. (2022), “BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update”, Journal of Hepatology. 76(3), pp. 681-693.